Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.
Last trade$23.41
Day change-$0.06 (-0.26%)
Day range$23.06 – $23.90
Volume439,816
Market cap$2.93B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$2.93B
Price / earnings
—
Price / book
5.2×
Price / sales
6.63×
EV / sales
5.96×
EV / EBITDA
-10.06×
Profitability
Earnings per share
-$1.59
Return on assets
-19.38%
Return on equity
-35.22%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.45×
Current ratio
2.04×
Quick ratio
1.84×
Cash ratio
1.3×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$163.34M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for ZLAB, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$108.21M
$106.31M
$99.61M
$127.6M
$116.1M
$109.98M
$106.49M
$109.07M
Cost of revenue
$51.31M
$48.16M
$38.34M
$62.33M
$46.88M
$43M
$38.65M
$42.09M
Gross profit
$56.9M
$58.15M
$61.28M
$65.27M
$69.21M
$66.97M
$67.84M
$66.98M
Selling, general and administrative
$70.07M
$72.87M
$65.07M
$73.04M
$70.11M
$71.04M
$63.42M
$82.62M
Research and development
$49.81M
$61.77M
$65.59M
$61.63M
$47.93M
$50.61M
$60.73M
$52.25M
Total operating expenses
$119.88M
$134.64M
$130.66M
$134.67M
$118.03M
$121.87M
$124.15M
$134.87M
Operating income
-$62.98M
-$76.49M
-$69.39M
-$69.41M
-$48.82M
-$54.9M
-$56.31M
-$67.89M
Interest expense
-$1.58M
-$1.59M
-$1.64M
-$1.36M
-$1.4M
-$1.26M
-$1.19M
-$904K
Income before taxes
-$48.01M
-$51.85M
-$49.58M
-$53.34M
-$35.96M
-$40.73M
-$48.44M
-$81.68M
Income taxes
-$1.87M
-$1.02M
$1.44M
-$2.93M
$0
$0
$0
$0
Net income
-$46.14M
-$50.83M
-$51.02M
-$50.41M
-$35.96M
-$40.73M
-$48.44M
-$81.68M
Net income attributable to common shareholders
-$46.14M
-$50.83M
-$51.02M
-$50.41M
-$35.96M
-$40.73M
-$48.44M
-$81.68M
EBITDA
-$58.57M
-$72.32M
-$65.44M
-$65.49M
-$44.92M
-$51.16M
-$52.85M
-$64.86M
Basic earnings per share
-$0.04
-$0.05
-$0.05
-$0.05
-$0.03
-$0.04
-$0.04
-$0.08
Diluted earnings per share
-$0.04
-$0.05
-$0.05
-$0.05
-$0.03
-$0.04
-$0.04
-$0.08
Recent news
Company coverage with links to the original publishers.
The article compares Amgen and Vertex Pharmaceuticals as investment options for 2027. Amgen offers diversified revenue streams across multiple drug franchises with lower valuation metrics but faces biosimilar competition and pricing pressures. Vertex demonstrates faster growth driven by cystic fibrosis dominance and promising pipeline candidates like Povetacicept, though at a premium valuation. The analyst recommends Vertex for long-term growth investors despite higher valuations, citing its superior growth trajectory and innovative pipeline.
Boehringer Ingelheim and Zai Lab announced a clinical collaboration to evaluate a dual DLL3-targeting combination therapy for small cell lung cancer (SCLC) and neuroendocrine carcinomas. The Phase Ib/II study will test obrixtamig, a DLL3/CD3 T-cell engager, combined with zocilurtatug pelitecan (zoci), a DLL3-targeting ADC. Both drugs have shown encouraging early efficacy and favorable safety profiles in previous trials.
The FDA has accelerated oncology drug approvals with over 50 approvals in 2025 and increased expedited designations in 2026. Multiple biotech companies are advancing cancer treatments through Fast Track and Breakthrough Therapy designations, targeting high-unmet-need solid tumors. Key developments include Oncolytics' pelareorep showing significant survival benefits in colorectal cancer, Relay's zovegalisib receiving Breakthrough designation for breast cancer, MAIA's ateganosine advancing in lung cancer, Zai Lab's AUGTYRO approval in China, and Arrivent's firmonertinib entering pivotal Phase 3 trials for NSCLC.
Chinese biopharma firm Zai Lab experienced a significant stock decline after disappointing Phase 3 trial results for its gastric cancer drug bemarituzumab and underwhelming quarterly earnings, with weak sales of core products impacting investor confidence.
Several biotech companies are advancing cancer research with promising clinical milestones, focusing on innovative immunotherapies and targeted treatments amid rising cancer incidence and potential research funding challenges.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.